NCT06303583View on ClinicalTrials.gov

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2026

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

paclitaxel

paclitaxel, 50 mg/m2, QW\*5

DRUG

carboplatin

area under the curve of2mg/mL/min, QW\*5

DRUG

tislelizumab

200mg Q3W, 2cycles

RADIATION

radiotherapy

41.4Gy in 23 fractions

Trial Locations (1)

310000

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Qiu Guoqin

OTHER